BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36983016)

  • 1. The Effect of Cholesterol in MCF7 Human Breast Cancer Cells.
    Albi E; Mandarano M; Cataldi S; Ceccarini MR; Fiorani F; Beccari T; Sidoni A; Codini M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth.
    Chai Y; Lee HJ; Shaik AA; Nkhata K; Xing C; Zhang J; Jeong SJ; Kim SH; Lu J
    Breast Cancer Res; 2010; 12(5):R67. PubMed ID: 20809980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingomyelin Metabolism Modifies Luminal A Breast Cancer Cell Line under a High Dose of Vitamin C.
    Codini M; Fiorani F; Mandarano M; Cataldi S; Arcuri C; Mirarchi A; Ceccarini MR; Beccari T; Kobayashi T; Tomishige N; Sidoni A; Albi E
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gentamicin Targets Acid Sphingomyelinase in Cancer: The Case of the Human Gastric Cancer NCI-N87 Cells.
    Albi E; Cataldi S; Ceccarini MR; Conte C; Ferri I; Fettucciari K; Patria FF; Beccari T; Codini M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31489901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.
    Garbar C; Mascaux C; Giustiniani J; Merrouche Y; Bensussan A
    Sci Rep; 2017 Aug; 7(1):7201. PubMed ID: 28775276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
    Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
    Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear Receptors Are Differentially Expressed and Activated in KAIMRC1 Compared to MCF7 and MDA-MB231 Breast Cancer Cells.
    Nehdi A; Ali R; Alhallaj A; Alzahrani H; Samman N; Mashhour A; Baz O; Barhoumi T; Alghanem B; Khan A; Alriyees L; Boudjelal M
    Molecules; 2019 May; 24(11):. PubMed ID: 31141879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.
    Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Wu CW; Lui WY
    Eur J Clin Invest; 2006 Aug; 36(8):588-96. PubMed ID: 16893382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA‑125a‑5p controls the proliferation, apoptosis, migration and PTEN/MEK1/2/ERK1/2 signaling pathway in MCF‑7 breast cancer cells.
    Liang Z; Pan Q; Zhang Z; Huang C; Yan Z; Zhang Y; Li J
    Mol Med Rep; 2019 Nov; 20(5):4507-4514. PubMed ID: 31702027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Yamamoto T; Kanaya N; Somlo G; Chen S
    Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the Ubiquitin-Specific Peptidase 9 X-Linked (USP9X) Gene is Associated with Upregulation of Cyclin D1 (CCND1) and Downregulation of Cyclin-Dependent Inhibitor Kinase 1A (CDKN1A) in Breast Cancer Tissue and Cell Lines.
    Li H; Zheng B
    Med Sci Monit; 2019 Jun; 25():4207-4216. PubMed ID: 31169265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
    Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
    Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent Activity of the Pseudogene
    Yndestad S; Austreid E; Skaftnesmo KO; Lønning PE; Eikesdal HP
    Mol Cancer Res; 2018 Jan; 16(1):78-89. PubMed ID: 29021233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hypoxia on human equilibrative nucleoside transporters hENT1 and hENT2 in breast cancer.
    Krys D; Hamann I; Wuest M; Wuest F
    FASEB J; 2019 Dec; 33(12):13837-13851. PubMed ID: 31601121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
    Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
    Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers.
    Vassilev B; Sihto H; Li S; Hölttä-Vuori M; Ilola J; Lundin J; Isola J; Kellokumpu-Lehtinen PL; Joensuu H; Ikonen E
    Am J Pathol; 2015 Apr; 185(4):987-1000. PubMed ID: 25681734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.
    Abdalla AN; Qattan A; Malki WH; Shahid I; Hossain MA; Ahmed M
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Bennett L; Quinn J; McCall P; Mallon EA; Horgan PG; McMillan DC; Paul A; Edwards J
    Int J Cancer; 2017 Apr; 140(7):1633-1644. PubMed ID: 28006839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.